Advertisement

Topics

Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit

22:53 EDT 29 Jun 2017 | Biotech-Finances

Thursday, June 29th 2017 at 9:35pm UTC Extended RAS Panel helps identify colorectal cancer patients eligible for Amgen’s Vectibix SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NASDAQ:ILMN) today announced its Extended RAS Panel, an FDA-approved next-generation sequencing (NGS) kit that meets the newly published guidelines for evaluation of colorectal cancer from the American Society for Clinical Pathology …

Cet article Illumina Announces FDA-approved Next-Generation Sequencing Cancer
Companion Diagnostic Test Kit
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit

NEXT ARTICLE

More From BioPortfolio on "Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...